Novozymes seeks partner to develop groundbreaking new antibiotic  

Denmark's Novozymes is seeking a partner from the pharmaceutical industry to further develop plectasin, an antimicrobial peptide (AMP) active against multi-resistant bacteria

As reported yesterday by Invest in Denmark, Novozymes has discovered a new antimicrobial peptide (AMP), plectasin, active against multi-resistant bacteria that pose a threat to global health. The groundbreaking discovery was published yesterday in the renowned international scientific journal Nature. The development of plectasin is at a very early preclinical phase, and Novozymes is seeking a partner from the pharmaceutical industry to further develop the new antibiotic.

Ejner Bech Jensen, research director for molecular biology at Novozymes says: "Our plan is to find a pharma company with a shared interest in developing this together with us. It needs to be a company with experience in developing antibiotic products and conducting clinical trials, and also a company with coverage of the market. Naturally we are most interested in large companies, because the potential is greater".

An antibiotic product could be marketed in 8-10 years provided that Novozymes successfully completes the development. The news was reported by national newspaper Børsen and on the Novozymes website.

Novozymes is the biotech-based world leader in enzymes and microorganisms. Headquartered in Bagsværd on the outskirts of Copenhagen, the company employs 4,000 people, half of whom are stationed in Denmark. Novozymes' 700 products are a key factor in the production of thousands of products used in everyday life. The company's B shares are listed on Copenhagen Stock Exchange.

Link > Novozymes 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×